Neuraxpharm enters the medical cannabis market

April 1, 2020 | Health Care Marketing

Neuraxpharm has entered into an agreement with Panaxia Labs Israel to distribute and market medical cannabis products in Germany. 

The CNS pharmaceutical company Neuraxpharm from Langenfeld near Düsseldorf is adding medical cannabis products to its portfolio. The company selected Panaxia Labs Israel, an Israeli medical cannabis manufacturer, as a partner to collaborate in the manufacturing, marketing and distribution of advanced medical cannabis products in Germany. The agreement contains the mutual option to consider extending the cooperation to other EU countries, Neuraxpharm announced. The establishment of the collaboration reflects the strategy of Neuraxpharm and Panaxia, to become a leading European provider of medical cannabis products. The first sales of Panaxia / Neuraxpharm medical cannabis products in Germany could take place in 2020 after receiving regulatory approval.

Read More On: Health Care Marketing Website

Share on linkedin
Share on facebook
Share on twitter